4.2 Article

The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?

期刊

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
卷 22, 期 7, 页码 535-544

出版社

CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2022.01.013

关键词

Multiple myeloma; High-risk; 1q21 gain/amplification

资金

  1. Capital's Funds for Health Improvement and Research [2020-2-4082]

向作者/读者索取更多资源

In this study, we conducted a retrospective study on 161 Chinese patients with newly diagnosed multiple myeloma to clarify the importance of the FISH cut-off value and copy number variation for 1q21. The results demonstrated that 5% was a reliable threshold for 1q21+ and >= 4 copies of 1q21 should be considered high risk for early progression or death.
To clarify the importance of the FISH cut-off value and copy number variation for 1q21 in Chinese newly diagnosed multiple myeloma, we performed a retrospective study in 161 patients. Our results showed that 5% was determined to be a reliable threshold for 1q21+ and >= 4 copies of 1q21 should be considered high risk for early progression or death. Background: The cut-off value for gain/amplification of 1q21(1q21+) was 20% according to the recommendations of the European Myeloma Network and there were limited studies concerning less than 20%. Meanwhile, the copy number variation of 1q21+ remains controversial. Our purpose was to evaluate the significance of clone size and copy numbers of 1q21+ in Chinese newly diagnosed multiple myeloma (NDMM). Patients and methods: We retrospectively analyzed 161 consecutive NDMM patients who were tested for common cytogenetic abnormalities at diagnosis by fluorescence in-situ hybridization and 5% was set for the threshold for 1q21+ by a comparative study. Results: Ninety-six (59.6%) patients were determined for 1q21+ by fluorescence in-situ hybridization including 38 had >= 4 copies. In clone size analyses, the 2-year progression-free survival (PFS) in <5% group was superior in comparison with 5% to 20% (65.2% vs. 47.0%, P=.041) and >20% group (65.2% vs. 37.5%, P<.001), whereas there was no significant difference between the 2 latter groups. Patients with >= 4 copies of 1q21 had inferior 2-year PFS compared to patients with 3 copies (23.3% vs. 50.6%, P=.028) and 2 copies (23.3% vs. 65.2%, P<.001). Bortezomib-based treatment might benefit the PFS for patients with 3 copies but could not improve the adverse effect of >= 4 copies. 1q21+ was an independent risk factor for inferior PFS and OS in multivariate analysis (P<.001 and P=.028). Conclusion: Our results demonstrated that 5% was a reliable cut-off value for 1q21+, and 1q21+ was an adverse prognostic factor in NDMM, especially when >= 4 copies were present. (C) 2022 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据